These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 26644315)

  • 1. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.
    Russo M; Siravegna G; Blaszkowsky LS; Corti G; Crisafulli G; Ahronian LG; Mussolin B; Kwak EL; Buscarino M; Lazzari L; Valtorta E; Truini M; Jessop NA; Robinson HE; Hong TS; Mino-Kenudson M; Di Nicolantonio F; Thabet A; Sartore-Bianchi A; Siena S; Iafrate AJ; Bardelli A; Corcoran RB
    Cancer Discov; 2016 Feb; 6(2):147-153. PubMed ID: 26644315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The genomic landscape of response to EGFR blockade in colorectal cancer.
    Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
    Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
    Siravegna G; Mussolin B; Buscarino M; Corti G; Cassingena A; Crisafulli G; Ponzetti A; Cremolini C; Amatu A; Lauricella C; Lamba S; Hobor S; Avallone A; Valtorta E; Rospo G; Medico E; Motta V; Antoniotti C; Tatangelo F; Bellosillo B; Veronese S; Budillon A; Montagut C; Racca P; Marsoni S; Falcone A; Corcoran RB; Di Nicolantonio F; Loupakis F; Siena S; Sartore-Bianchi A; Bardelli A
    Nat Med; 2015 Jul; 21(7):795-801. PubMed ID: 26030179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
    Bronte G; Silvestris N; Castiglia M; Galvano A; Passiglia F; Sortino G; Cicero G; Rolfo C; Peeters M; Bazan V; Fanale D; Giordano A; Russo A
    Oncotarget; 2015 Sep; 6(28):24780-96. PubMed ID: 26318427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis.
    Bouchahda M; Karaboué A; Saffroy R; Innominato P; Gorden L; Guettier C; Adam R; Lévi F
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):605-9. PubMed ID: 20361188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer.
    Siravegna G; Lazzari L; Crisafulli G; Sartore-Bianchi A; Mussolin B; Cassingena A; Martino C; Lanman RB; Nagy RJ; Fairclough S; Rospo G; Corti G; Bartolini A; Arcella P; Montone M; Lodi F; Lorenzato A; Vanzati A; Valtorta E; Cappello G; Bertotti A; Lonardi S; Zagonel V; Leone F; Russo M; Balsamo A; Truini M; Di Nicolantonio F; Amatu A; Bonazzina E; Ghezzi S; Regge D; Vanzulli A; Trusolino L; Siena S; Marsoni S; Bardelli A
    Cancer Cell; 2018 Jul; 34(1):148-162.e7. PubMed ID: 29990497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
    Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
    J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?
    Baretti M; Personeni N; Destro A; Santoro A; Rimassa L
    Cancer Biol Ther; 2018 Aug; 19(8):659-663. PubMed ID: 29580164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
    Bardelli A; Siena S
    J Clin Oncol; 2010 Mar; 28(7):1254-61. PubMed ID: 20100961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
    Gray ES; Rizos H; Reid AL; Boyd SC; Pereira MR; Lo J; Tembe V; Freeman J; Lee JH; Scolyer RA; Siew K; Lomma C; Cooper A; Khattak MA; Meniawy TM; Long GV; Carlino MS; Millward M; Ziman M
    Oncotarget; 2015 Dec; 6(39):42008-18. PubMed ID: 26524482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.
    Lin JK; Lin AJ; Lin CC; Lan YT; Yang SH; Li AF; Chang SC
    J Surg Oncol; 2011 Nov; 104(6):661-6. PubMed ID: 21671463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics.
    Choi IS; Kato S; Fanta PT; Leichman L; Okamura R; Raymond VM; Lanman RB; Lippman SM; Kurzrock R
    Mol Cancer Ther; 2019 Oct; 18(10):1852-1862. PubMed ID: 31320401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.
    Chen D; Huang X; Cai J; Guo S; Qian W; Wery JP; Li QX
    Oncotarget; 2015 Dec; 6(38):40815-21. PubMed ID: 26512781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spatiotemporal Heterogeneity across Metastases and Organ-Specific Response Informs Drug Efficacy and Patient Survival in Colorectal Cancer.
    Zhou J; Li Q; Cao Y
    Cancer Res; 2021 May; 81(9):2522-2533. PubMed ID: 33589516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
    Song QB; Wang Q; Hu WG
    World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.
    Li W; Shi Q; Wang W; Liu J; Ren J; Li Q; Hou F
    Colorectal Dis; 2014 Nov; 16(11):O370-8. PubMed ID: 25155261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and molecular assessment of regorafenib monotherapy.
    Kakizawa N; Suzuki K; Fukui T; Takayama Y; Ichida K; Muto Y; Hasegawa F; Watanabe F; Kikugawa R; Tsujinaka S; Futsuhara K; Miyakura Y; Noda H; Rikiyama T
    Oncol Rep; 2017 Apr; 37(4):2506-2512. PubMed ID: 28259999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
    Fabian P; Berkovcová J
    Cesk Patol; 2011 Oct; 47(4):154-8. PubMed ID: 22145213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.